Tasnin Al Hasib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tasnin Al Hasib has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Kazi Ahsan Ahmed
ABEx Bio‐Research Center Dhaka Bangladesh
5 shared publications - Jamal Uddin
ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
4 shared publications - Shamrat Kumar Paul
Department of Physics and Astronomy, College of Science, Clemson University, Clemson, SC 29634, USA
3 shared publications - Abu Saim Mohammad Saikat
Department of Computational Biology and Bioinformatics, Advanced Bioscience Center for Collaborative Research (ABSCCR), Rajshahi 6250, Bangladesh
2 shared publications Abul Bashar Ripon Khalipha
Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh
2 shared publications- Ataur Rahman
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
2 shared publications
Latest Publications
- Open Access
- 26 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4972-4985
Potential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives
CCNs are a specific type of matricellular protein, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members, which exist only in vertebrates. The architecture of CCN proteins is multi-modular comprising four distinct modules. CCN Proteins achieve their primary functional activities by binding with several integrin7 receptors. The CCN family has been linked to cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, chondrogenesis, and wound healing, among other biological interactions. Breast cancer is the most commonly diagnosed cancer worldwide and CCN regulated breast cancer stands at the top. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. The pro-tumorigenic CCN1, CCN2, CCN3, and CCN4 may lead to human breast cancer, although the anti-tumorigenic actions of CCN5 and CCN6 are also present. Several studies have been conducted on CCN proteins and cancer in recent years. CCN1 and CCN3 have been shown to exhibit a dual nature of tumor inhibition and tumor suppression to some extent in quiet recent time. Pharmacological advances in treating breast cancer by targeting CCN proteins are also reported. In our study, we intend to provide an overview of these research works while keeping breast cancer in focus. This information may facilitate early diagnosis, early prognosis and the development of new therapeutic strategies.
- 26 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4972-4985
Open AccessPotential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives
CCNs are a specific type of matricellular protein, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members, which exist only in vertebrates. The architecture of CCN proteins is multi-modular comprising four distinct modules. CCN Proteins achieve their primary functional activities by binding with several integrin7 receptors. The CCN family has been linked to cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, chondrogenesis, and wound healing, among other biological interactions. Breast cancer is the most commonly diagnosed cancer worldwide and CCN regulated breast cancer stands at the top. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. The pro-tumorigenic CCN1, CCN2, CCN3, and CCN4 may lead to human breast cancer, although the anti-tumorigenic actions of CCN5 and CCN6 are also present. Several studies have been conducted on CCN proteins and cancer in recent years. CCN1 and CCN3 have been shown to exhibit a dual nature of tumor inhibition and tumor suppression to some extent in quiet recent time. Pharmacological advances in treating breast cancer by targeting CCN proteins are also reported. In our study, we intend to provide an overview of these research works while keeping breast cancer in focus. This information may facilitate early diagnosis, early prognosis and the development of new therapeutic strategies.
- 11 November 2021
- Published by Universal Wiser Publisher Pte. Ltd in Applied Microbiology: Theory & Technology
- p. 83-99
In-Silico Molecular Docking and Pharmaco-Kinetic Activity Analysis of Potential Inhibitors against SARS-CoV-2 Spike Glycoproteins
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a causative agent of the potentially fatal coronavirus disease (COVID-19). Coronavirus targets the human respiratory system primarily. It can also infect the gastrointestinal, hepatic, and central nervous systems of humans, avians, bats, livestock, mice, and many other wild animals, as these are primary targets of the pathogen. This study aims to screen out the most potent inhibitor for SARS-CoV-2 (COVID-19) spike glycoproteins among the selected drugs, and computational tools have been utilized for this purpose. The selected drugs have been designed to explore their structural properties in this study by molecular orbital calculation. To inhibit the spike glycoproteins, the performance of these drugs was also examined by molecular docking calculation. In improving the performance of drugs, non-bond interactions play a significant role. To determine the chemical reactivity of all the medicines, HOMO and LUMO energy values were also calculated. The combined calculations exhibited that Ledipasvir among the selected drugs can be the most potent drug to treat SARS-CoV-2 compared to other medications.
- 11 November 2021
- Published by Universal Wiser Publisher Pte. Ltd in Applied Microbiology: Theory & Technology
- p. 83-99
In-Silico Molecular Docking and Pharmaco-Kinetic Activity Analysis of Potential Inhibitors against SARS-CoV-2 Spike Glycoproteins
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a causative agent of the potentially fatal coronavirus disease (COVID-19). Coronavirus targets the human respiratory system primarily. It can also infect the gastrointestinal, hepatic, and central nervous systems of humans, avians, bats, livestock, mice, and many other wild animals, as these are primary targets of the pathogen. This study aims to screen out the most potent inhibitor for SARS-CoV-2 (COVID-19) spike glycoproteins among the selected drugs, and computational tools have been utilized for this purpose. The selected drugs have been designed to explore their structural properties in this study by molecular orbital calculation. To inhibit the spike glycoproteins, the performance of these drugs was also examined by molecular docking calculation. In improving the performance of drugs, non-bond interactions play a significant role. To determine the chemical reactivity of all the medicines, HOMO and LUMO energy values were also calculated. The combined calculations exhibited that Ledipasvir among the selected drugs can be the most potent drug to treat SARS-CoV-2 compared to other medications.
- Open Access
An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma
Glial cells comprise the non-sensory parts of the central nervous system as well as the peripheral nervous system. Glial cells, also known as neuroglia, constitute a significant portion of the mammalian nervous system and can be viewed simply as a matrix of neural cells. Despite being the “Nervenkitt” or “glue of the nerves”, they aptly serve multiple roles, including neuron repair, myelin sheath formation, and cerebrospinal fluid circulation. Ependymal cells are one of four kinds of glial cells that exert distinct functions. Tumorigenesis of a glial cell is termed a glioma, and in the case of an ependymal cell, it is called an ependymoma. Among the various gliomas, an ependymoma in children is one of the more challenging brain tumors to cure. Children are afflicted more severely by ependymal tumors than adults. It has appeared from several surveys that ependymoma comprises approximately six to ten percent of all tumors in children. Presently, the surgical removal of the tumor is considered a standard treatment for ependymomas. It has been conspicuously evident that a combination of irradiation therapy and surgery is much more efficacious in treating ependymomas. The main purpose of this review is to present the importance of both a deep understanding and ongoing research into histopathological features and prognoses of ependymomas to ensure that effective diagnostic methods and treatments can be developed.
Open AccessAn Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma
Glial cells comprise the non-sensory parts of the central nervous system as well as the peripheral nervous system. Glial cells, also known as neuroglia, constitute a significant portion of the mammalian nervous system and can be viewed simply as a matrix of neural cells. Despite being the “Nervenkitt” or “glue of the nerves”, they aptly serve multiple roles, including neuron repair, myelin sheath formation, and cerebrospinal fluid circulation. Ependymal cells are one of four kinds of glial cells that exert distinct functions. Tumorigenesis of a glial cell is termed a glioma, and in the case of an ependymal cell, it is called an ependymoma. Among the various gliomas, an ependymoma in children is one of the more challenging brain tumors to cure. Children are afflicted more severely by ependymal tumors than adults. It has appeared from several surveys that ependymoma comprises approximately six to ten percent of all tumors in children. Presently, the surgical removal of the tumor is considered a standard treatment for ependymomas. It has been conspicuously evident that a combination of irradiation therapy and surgery is much more efficacious in treating ependymomas. The main purpose of this review is to present the importance of both a deep understanding and ongoing research into histopathological features and prognoses of ependymomas to ensure that effective diagnostic methods and treatments can be developed.
- Open Access
- 28 January 2021
- Published by MDPI AG in Preprints.org
The Aspects of CCN Protein Family on Breast Cancer
CCNs are specific type of matricellular proteins, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members in mammals. The architecture of CCN proteins is multimodular and comprises four distinct motifs. CCN proteins achieve their specific physiological functions by binding to integrin receptors. The CCN family has been implicated in both cure and disease with impacts on biological interactions, such as cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, immune functions, chondrogenesis, and wound healing. Breast cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer mortality among women triggered by atypical expression of CCNs. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. Aberrant expression of CCN1 intensifies the proliferation of epithelial cells that line the lobes and ducts of the breast. Evidence also shows that the expression of CCN2 can ameliorate tumor growth and metastasis. However, CCN3 (NOV), CCN5 (WISP-2), and CCN6 (WISP-3) are consistent with neoplastic development and metastasis repression. Particular CCN members can develop tumors and cancer progression, whereas others can competitively counter the processes. Several studies have been conducted on CCN proteins and cancer in recent years. In our study, we intend to provide an overview of those research works while keeping breast carcinoma on focus. We believe that the importance of the CCN protein family in breast cancer should be reconsidered.
- 28 January 2021
- Published by MDPI AG in Preprints.org
Open AccessThe Aspects of CCN Protein Family on Breast Cancer
CCNs are specific type of matricellular proteins, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members in mammals. The architecture of CCN proteins is multimodular and comprises four distinct motifs. CCN proteins achieve their specific physiological functions by binding to integrin receptors. The CCN family has been implicated in both cure and disease with impacts on biological interactions, such as cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, immune functions, chondrogenesis, and wound healing. Breast cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer mortality among women triggered by atypical expression of CCNs. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. Aberrant expression of CCN1 intensifies the proliferation of epithelial cells that line the lobes and ducts of the breast. Evidence also shows that the expression of CCN2 can ameliorate tumor growth and metastasis. However, CCN3 (NOV), CCN5 (WISP-2), and CCN6 (WISP-3) are consistent with neoplastic development and metastasis repression. Particular CCN members can develop tumors and cancer progression, whereas others can competitively counter the processes. Several studies have been conducted on CCN proteins and cancer in recent years. In our study, we intend to provide an overview of those research works while keeping breast carcinoma on focus. We believe that the importance of the CCN protein family in breast cancer should be reconsidered.
- 1 January 2020
- Published by ScopeMed in Journal of Advanced Biotechnology and Experimental Therapeutics
- Vol. 3 (4) , 30
Current knowledge on mechanisms involved in SARS-CoV-2 infection and kidney diseases
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is cause of a global pandemic which is demolishing global health and economy. SARS-CoV-2 infected patients are hospitalized with pneumonia where almost 20-30% of patients are led to kidney failure. The entry of SARS-CoV-2 into the systemic circulation leads to acute kidney injury (AKI) which may develop chronic kidney disease (CKD). In addition, patients who are diagnosed with AKI or CKD are at major risk of SARS-CoV-2 infection. Although a significant number of compounds have been proposed and the existing drugs have also been tested for repurposing, no specific therapy has been approved yet. SARS-CoV-2 invades human cells binding to the receptor of angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain. Cells that express ACE2 are susceptible to SARS-CoV-2 infection and the proportion of ACE2-positive cells in kidney proximal tubule is approximately 4%, indicating that SARS-CoV-2 might damage the kidney tubules leading to fatal kidney injury. Therefore, a better understanding of the potential mechanisms involved in SARS-CoV-2 infection-mediated kidney disease may unveil a novel therapeutic strategy against kidney diseases during COVID-19.
- 1 January 2020
- Published by ScopeMed in Journal of Advanced Biotechnology and Experimental Therapeutics
- Vol. 3 (4) , 30
Current knowledge on mechanisms involved in SARS-CoV-2 infection and kidney diseases
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is cause of a global pandemic which is demolishing global health and economy. SARS-CoV-2 infected patients are hospitalized with pneumonia where almost 20-30% of patients are led to kidney failure. The entry of SARS-CoV-2 into the systemic circulation leads to acute kidney injury (AKI) which may develop chronic kidney disease (CKD). In addition, patients who are diagnosed with AKI or CKD are at major risk of SARS-CoV-2 infection. Although a significant number of compounds have been proposed and the existing drugs have also been tested for repurposing, no specific therapy has been approved yet. SARS-CoV-2 invades human cells binding to the receptor of angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain. Cells that express ACE2 are susceptible to SARS-CoV-2 infection and the proportion of ACE2-positive cells in kidney proximal tubule is approximately 4%, indicating that SARS-CoV-2 might damage the kidney tubules leading to fatal kidney injury. Therefore, a better understanding of the potential mechanisms involved in SARS-CoV-2 infection-mediated kidney disease may unveil a novel therapeutic strategy against kidney diseases during COVID-19.
- 20 November 2019
- Published by Taylor & Francis
- p. 179-184
Structure prediction and functional characterization of uncharacterized protein Rv1708 of Mycobacterium tuberculosis (Strain ATCC 25618/H37Rv)
Tuberculosis (TB) is one of the most known ancient human disease which is caused by Mycobacterium Tuberculosis (MTB). Surprisingly, at present it is one of the major causes of death of human around the globe. Complete genome sequencing of MTB provides us a storehouse of genomic information to study about MTB’s complex pathogenicity. Among 3924 Open Reading frame of MTB, the Uncharacterized Protein Rv1708 is encoded by Rv1708 gene and it is a inferred to be a cell cycle regulatory protein. It is anticipated that during cell division the Uncharacterized Protein Rv1708 play a critical role in septum formation of MTB. Thus, it becomes the mediator of cell cycle progression and cell division. Inhibition of bacterial cell division by blocking its associated protein is known to be therapeutic target for defeating disease. But the Uncharacterized Protein Rv1708 of the MTB remained unexplored. So, our aim is to propose the structural and functional features in addition to reveal the physicochemical properties. Homology modelling of the Uncharacterized Protein Rv1708 was generated by using Phyre2 and Swiss Model. The in-stability index generated by using the ExPasy’s ProtParam tool shows that the Uncharacterized Protein Rv1708 is stable and its nature is acidic. Ramachandran map analysis by MolProbity reveals 95.5% of all residues were in allowed regions and 87.7% of all residues were in favored regions; which is indicating strong evidence of good quality of protein structure. This in-silico process will unveil the role of unexplored Uncharacterized Protein Rv1708 of MTB, and so it can pave the way for enriching our knowledge of the pathogenesis and drug-targeting approach for MTB.
- 20 November 2019
- Published by Taylor & Francis
- p. 179-184
Structure prediction and functional characterization of uncharacterized protein Rv1708 of Mycobacterium tuberculosis (Strain ATCC 25618/H37Rv)
Tuberculosis (TB) is one of the most known ancient human disease which is caused by Mycobacterium Tuberculosis (MTB). Surprisingly, at present it is one of the major causes of death of human around the globe. Complete genome sequencing of MTB provides us a storehouse of genomic information to study about MTB’s complex pathogenicity. Among 3924 Open Reading frame of MTB, the Uncharacterized Protein Rv1708 is encoded by Rv1708 gene and it is a inferred to be a cell cycle regulatory protein. It is anticipated that during cell division the Uncharacterized Protein Rv1708 play a critical role in septum formation of MTB. Thus, it becomes the mediator of cell cycle progression and cell division. Inhibition of bacterial cell division by blocking its associated protein is known to be therapeutic target for defeating disease. But the Uncharacterized Protein Rv1708 of the MTB remained unexplored. So, our aim is to propose the structural and functional features in addition to reveal the physicochemical properties. Homology modelling of the Uncharacterized Protein Rv1708 was generated by using Phyre2 and Swiss Model. The in-stability index generated by using the ExPasy’s ProtParam tool shows that the Uncharacterized Protein Rv1708 is stable and its nature is acidic. Ramachandran map analysis by MolProbity reveals 95.5% of all residues were in allowed regions and 87.7% of all residues were in favored regions; which is indicating strong evidence of good quality of protein structure. This in-silico process will unveil the role of unexplored Uncharacterized Protein Rv1708 of MTB, and so it can pave the way for enriching our knowledge of the pathogenesis and drug-targeting approach for MTB.